Elafibranor

Drug Profile

Elafibranor

Alternative Names: GFT-505

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Genfit
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Primary biliary cirrhosis
  • Preclinical Hepatic fibrosis; Non-alcoholic fatty liver disease
  • No development reported Lipid metabolism disorders; Type 2 diabetes mellitus

Most Recent Events

  • 05 Apr 2017 Phase-II clinical trials in Primary biliary cirrhosis (Treatment-resistant) in Europe (PO)
  • 05 Apr 2017 Phase-II clinical trials in Primary biliary cirrhosis (Treatment-resistant) in USA (PO) (NCT03124108)
  • 08 Feb 2017 The US FDA approves launch of phase II trial for elafibranor in Primary biliary cirrhosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top